What I was referring to was the Phase 2 trial that preceded
the Phase 3 trial. It was based on the excellent outcomes of that Phase 2 trial that they went ahead with the Phase 3 trial.
It may be that earlier in progression makes all the difference. Or it may be that there are certain biochemical markers (e.g., ability to produce killer T cells) that are determinative. We can't know until they do the analytic work.
Allen - not an MD
•PSA=7.3, prostate volume=55cc, 8/17 cores G6 5-35% involvement
•SBRT 9 yr onc. results
•SBRT 7 yr QOL results
•treated 10/2010 at age 57 at UCLA,PSA now: 0.1,no lasting urinary, rectal or sexual SEsmy PC blog